David Sharon

David Sharon

Partner

Life Sciences and Tech Expertise

David has extensive experience working with biotech, pharmaceutical, software, cybersecurity, fintech, and autonomous trucking companies through all stages of their growth.
Capital Markets, Corporate, and Securities Expertise

David has represented clients in a broad range of corporate and securities matters including IPOs, deSPACs and other offerings, corporate governance, and other transactional matters. He has also worked on numerous transactions as underwriter counsel.

David Sharon is a partner in Wilson Sonsini Goodrich & Rosati’s New York office, where he focuses on corporate and securities work for both public and private companies across all stages of growth. David’s broad capital markets experience includes initial public, follow-on, and secondary equity offerings; investment grade, high-yield, and convertible debt offerings; and private investment in public equity (PIPE) transactions.

He also counsels publicly held companies on general corporate representation, SEC compliance, disclosure matters, exchange-listing standards, and complex securities law issues, and frequently represents investment banks in their underwriting transactions.

Prior to joining Wilson Sonsini, David practiced law at Fried, Frank, Harris, Shriver & Jacobson LLP in New York.

Experience

Prior to joining Wilson Sonsini, David practiced law at Fried, Frank, Harris, Shriver & Jacobson LLP in New York.

Education

J.D., Cornell Law School, 2013
M.B.A., S.C. Johnson Graduate School of Management, Cornell University, 2013
B.S., Cornell University, School of Industrial and Labor Relations, 2009

Admissions

State Bar of New York

Credentials

Education

J.D., Cornell Law School, 2013
M.B.A., S.C. Johnson Graduate School of Management, Cornell University, 2013
B.S., Cornell University, School of Industrial and Labor Relations, 2009

Admissions

State Bar of New York

Recent Insights

Client Highlights

On May 4, 2026, Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, announced an upsized $165 million crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and Harbour BioMed. Wilson Sonsini Goodrich & Rosati represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in the transaction.

Since its launch in January 2025, Windward Bio has in-licensed two clinical-stage assets, raised $365 million, and rapidly advanced both programs in the clinic. The proceeds from this latest financing will significantly extend the company’s cash runway and enable multiple clinical readouts in the next 12 months.

The Wilson Sonsini team that represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in connection with the financing included:

Learn More

Client Highlights

On April 8, 2026, Forte Biosciences, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. The gross proceeds from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.

Learn More

View All

Recent Events

Affiliated Programs

Wilson Sonsini is proud to sponsor the NewYorkBIO Life Science Company Showcase and Reception on December 15, 2025 at the NYSE. Partner David Sharon will join industry leaders from 2:40 PM - 3:25 PM ET for the panel titled "IPO, M&A, or Alternative Pathways: Navigating the Next Exit Cycle." Panelists will explore routes to liquidity and market readiness for emerging companies. For more information please visit the Showcase website and the Reception website.

Learn More

Affiliated Programs

Join us for Brex Founder & VC Happy Hour in NYC and connect with fellow professionals and be part of a thriving community in New York during #TechWeek.

Learn More